All In MedTech

Device Trial Radar · NCT04362774

ORBERA365 Post-Marketing Clinical Follow-up Study

A Prospective, Multicenter, Open-label, Post-approval Study of the Safety and Effectiveness of ORBERA365 As a 12-month Adjunct to Weight Reduction for Obese Adults or Pre-surgical Weight Reduction for Obese or Super-obese Adults

Last checked: Nov 20, 2026Latest source record: Dec 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

25

Actual

Start

Feb 23, 2021

Primary completion

Feb 21, 2023

Study completion Oct 10, 2023

Sponsor

Lead sponsor
Apollo Endosurgery, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Apr 27, 2020

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A prospective, multicenter, open-label, post-approval study of the safety and effectiveness of ORBERA36 as a 12-month adjunct to weight reduction for obese adults (BMI ≥ 27 kg/m2 and BMI ≤ 50 kg/m2) or for pre-surgical weight reduction in obese and super-obese adults (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities).

Conditions

  • Obesity
  • Overweight

Interventions

  • ORBERA365Device

    Behavioral modification program in conjunction with endoscopic placement of a single ORBERA365 Intragastric Balloon, filled with saline to an inflation volume between 400cc and 700cc with 2mL of Methylene blue (10mg/mL)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Early Removal PercentTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Obymed

    Seville, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.